PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough.
View / Open Files
Authors
Wu, Zhe
Banya, Winston
Chaudhuri, Nazia
Jakupovic, Ira
Maher, Toby M
Patel, Brijesh
Spencer, Lisa G
Thillai, Muhunthan
West, Alex
Westoby, John
Wijsenbeek, Marlies
Smith, Jaclyn
Publication Date
2022-03-02Journal Title
Trials
ISSN
1745-6215
Publisher
Springer Science and Business Media LLC
Volume
23
Issue
1
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Wu, Z., Banya, W., Chaudhuri, N., Jakupovic, I., Maher, T. M., Patel, B., Spencer, L. G., et al. (2022). PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough.. Trials, 23 (1) https://doi.org/10.1186/s13063-022-06068-4
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive disease that leads to lung scarring. Cough is reported by 85% of patients with IPF and can be a distressing symptom with a significant impact on patients' quality of life. There are no proven effective therapies for IPF-related cough. Whilst morphine is frequently used as a palliative agent for breathlessness in IPF, its effects on cough have never been tested. PAciFy Cough is a multicenter, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of cough in IPF. METHODS: We will recruit 44 subjects with IPF prospectively from three interstitial lung disease units in the UK, namely the Royal Brompton Hospital, Manchester University NHS Foundation Trust (MFT) and Aintree University Hospital NHS Foundation Trust. Patients will be randomised (1:1) to either placebo twice daily or morphine sulphate 5 mg twice daily for 14 days. They will then crossover after a 7-day washout period. The primary endpoint is the percent change in daytime cough frequency (coughs per hour) from baseline as assessed by objective cough monitoring at day 14 of treatment. DISCUSSION: This multicentre, randomised trial will assess the effect of opioids on cough counts and cough associated quality of life in IPF subjects. If proven to be an effective intervention, it represents a readily available treatment for patients. TRIAL REGISTRATION: The study was approved by the UK Medicines and Healthcare Regulatory Agency (Ref: CTA 21268/0224/001-0001 - EUDRACT 2019-003571-19 - Protocol Number RBH2019/001) on 08 April 2020, in compliance with the European Clinical Trials Directive and the Medicines for Human Use (Clinical Trials) Regulations 2004 and its subsequent amendments. The study was provided with ethical approval by the London Brent Research Ethics Committee (Ref: 20/LO/0368) on 21 May 2020 and is registered with clinicaltrials.gov (NCT04429516) on 12 June 2020, available at https://clinicaltrials.gov/ct2/show/NCT04429516.
Keywords
Morphine, Quality of life, idiopathic pulmonary fibrosis, Cough, Interstitial Lung Disease, Humans, Treatment Outcome, Cross-Over Studies, Double-Blind Method, Quality of Life, Idiopathic Pulmonary Fibrosis
Sponsorship
National Institute for Health Research (NIHR) (NIHR200288)
Identifiers
35236391, PMC8889046
External DOI: https://doi.org/10.1186/s13063-022-06068-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335713
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk